The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
Dr. David Shoemaker of Rho discusses R&D trends and challenges, efforts to streamline drug development, and the greatest motivators for outsourcing in today’s market. Read it here.